Possible Liver Damage Leads to FDA Warning for Cardiac Drug

Multaq, a Sanofi-Avenitis drug approved to treat atrial flutter and atrial fibrillation in July 2009, has now received a warning about potentially fatal liver disease associated with the drug. Mutaq already carries with it a black box warning, the most severe warning, for a number of potential adverse health consequences.
In announcing the additional warning for liver toxicity, the FDA informed Multaq patients to contact their physicians if they experience any symptoms of liver problems such as nausea or vomiting.
The FDA warning comes in the wake of several reports of liver damage in Multaq users. Two of the reports included patients who had to have their livers removed after they used the drug-one for 4.5 months and the other for 6 months.